Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Seprafilm

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved August 1996

Specific Treatments:

reduction of scar tissue as a result of abdominal or pelvic surgery

General Information

Seprafilm bioresorbable membrane has been approved for use in any open abdominal or pelvic surgery. Seprafilm is indicated for use in subjects undergoing abdominal or pelvic open surgery as an adjunct intended to reduce the incidence, extent, and severity of postoperative adhesions (scar tissues) between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel, and bladder.

Clinical Results

The effect of Seprafilm on long-term postoperative complications (i.e. intestinal obstruction, female infertility, chronic pain) has not yet been studied, but two clinical trials have shown that Seprafilm reduced adhesion formation where the membrane was placed.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation